Flexion Therapeutics

Flexion Therapeutics, Inc.
Public
Traded as NASDAQ: FLXN
Russell 2000 Component
Industry Pharmaceuticals
Headquarters Burlington, MA
Website Flexion Therapeutics

Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.[1][2]

It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.[3]

In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".[4][5] In March 2017 FiercePharma reported that Flexion was in discussions with Sanofi about a possible acquisition, valued at the time at around $1 billion.[4]

Flexion had been developing FX007, a selective small-molecule TrkA inhibitor that it had licensed from AstraZeneca, for osteoarthritis.[6] As of March 2017 Flexion had terminated development.[7] Flexion had also terminated development of FX005, a P38 mitogen-activated protein kinase inhibitor, by that time.[8]

References

  1. ↑ Gormley, Brian. (28 November 2011). "Flexion Changes Endgame, Advances Osteoarthritis Drugs." Dow Jones VentureWire.
  2. ↑ Young, Robin (March 8, 2012). "Could This Be Orthopedics' Future?". Orthopedics This Week. Archived from the original on May 14, 2012.
  3. ↑ Weisman, Robert (December 12, 2016). "2 biotechs look to market knee pain treatments - The Boston Globe". Boston Globe.
  4. 1 2 Staton, Tracy (March 23, 2017). "Sanofi on verge of $1B-plus deal for arthritis-focused biotech Flexion: source". FiercePharma.
  5. ↑ "Triamcinolone acetonide sustained-release". AdisInsight. Retrieved 17 July 2017.
  6. ↑ Kavanaugh, Taylor E.; Werfel, Thomas A.; Cho, Hongsik; Hasty, Karen A.; Duvall, Craig L. (2015). "Particle-based technologies for osteoarthritis detection and therapy". Drug Delivery and Translational Research. doi:10.1007/s13346-015-0234-2. ISSN 2190-393X. PMC 4654703.
  7. ↑ "FX 007". AdisInsight. Retrieved 17 July 2017.
  8. ↑ "FX 005". AdisInsight. Retrieved 17 July 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.